MedTrace Logo

Aliskiren in Combination With Losartan Compared to Losartan on the Regression of Left Ventricular Hypertrophy in Overweight Patients With Essential Hypertension

NCT00219141 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 460

Last updated 2011-05-26

Study results available
· View outcomes & findings →

Summary

To compare the efficacy and safety of aliskiren in combination with losartan compared to losartan on the regression of the increased size of the left ventricle in overweight patients with high blood pressure.

Conditions

Interventions

DRUG

Aliskiren 150/300 mg

Aliskiren 150 mg tablets

DRUG

Losartan 50/100 mg

Losartan 50 or 100 mg capsules

DRUG

Aliskiren placebo

Aliskiren 150 mg placebo tablet

DRUG

Losartan 50/100 mg placebo

Losartan 50/100 mg placebo capsules

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-10-31
Primary Completion
2007-11-30
Completion
2007-11-30

Countries

  • United States
  • Argentina
  • Colombia
  • Finland
  • Germany
  • Italy
  • Russia
  • Spain
  • Sweden

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00219141 on ClinicalTrials.gov